Back to top
more

Ironwood Pharmaceuticals (IRWD)

(Delayed Data from NSDQ)

$7.88 USD

7.88
3,202,176

+0.06 (0.77%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $7.88 0.00 (0.00%) 5:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Esperion (ESPR) Q1 Earnings Miss, Lower Drug Price Hits Sales

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.

Pacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat

by Zacks Equity Research

Pacira's (PCRX) earnings in the first quarter of 2021 miss estimates while revenues beat the same. Exparel sales rise year over year.

Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q1 results.

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?

by Zacks Equity Research

Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.

Cambium (CMBM) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Cambium's (CMBM) first-quarter 2021 earnings are likely to have been driven by robust demand for superior broadband connectivity supported by a dynamic business model.

Aviat (AVNW) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Aviat's (AVNW) earnings in third-quarter fiscal 2021 are likely to have benefited from the increasing market traction of its microwave transport product and software offerings.

Is a Beat in Store for T-Mobile (TMUS) This Earnings Season?

by Zacks Equity Research

T-Mobile's (TMUS) revenues in the first quarter of 2021 are likely to have benefited from the Sprint merger and customer growth.

Ironwood Pharmaceuticals (IRWD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is a Beat in the Cards for Twist (TWS) This Earnings Season?

by Zacks Equity Research

Investors will focus on the top-line and bottom-line numbers when Twist (TWST) reports fiscal second-quarter 2021 results.

Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ironwood (IRWD) Q4 Earnings Beat on Solid Linzess Sales

by Zacks Equity Research

Ironwood (IRWD) witnesses strong demand for Linzess in the fourth quarter. However, outlook for 2021 misses market expectations.

Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ironwood (IRWD) delivered earnings and revenue surprises of 33.33% and 9.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline

by Zacks Equity Research

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

by Zacks Equity Research

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

Ocular's (OCUL) sNDA for Dextenza Gets FDA Acceptance, Shares Up

by Zacks Equity Research

The FDA accepts Ocular's (OCUL) sNDA for label expansion of Dextenza to treat ocular itching associated with allergic conjunctivitis. The FDA will give its verdict in October 2021. Shares rise.

J&J (JNJ) Begins Rolling BLA Filing of Multiple Myeloma Drug

by Zacks Equity Research

J&J (JNJ) initiates the rolling submission of its BLA to the FDA for BCMA CAR-T therapy, ciltacabtagene autoleucel to treat adults with relapsed/refractory multiple myeloma.

Ensign Group (ENSG) Rewards Shareholders With Dividend Hike

by Zacks Equity Research

Ensign Group's (ENSG) latest dividend hike indicates strong financial standing and continuous focus on boosting shareholders' value.

Karyopharm's (KPTI) Xpovio Gets FDA Nod for Second-Line Myeloma

by Zacks Equity Research

Karyopharm (KPTI) gets FDA approval for label expansion of its marketed drug, Xpovio, in combination with Takeda's Velcade and dexamethasone for treating multiple myeloma in second-line setting.

Ironwood (IRWD) Up 19.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

by Zacks Equity Research

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.

FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication

by Zacks Equity Research

FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.

    Can Ironwood (IRWD) Run Higher on Rising Earnings Estimates?

    by Zacks Equity Research

    Ironwood (IRWD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session

    by Zacks Equity Research

    Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

    Rimmi Singhi headshot

    5 High Earnings Yield Stocks to Add to Your Portfolio

    by Rimmi Singhi

    Earnings yield can be more illuminating than the traditional P/E ratio as the former facilitates comparison of stocks with fixed-income securities.